La vendita allo scoperto per Cytokinetics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cytokinetics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cytokinetics (NASDAQ:CYTK) Azioni, Report sulle vendite allo scoperto

Cytokinetics

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

Cantor Fitzgerald analyst Charles Duncan reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Overweight.

News

Reiteration

Analyst Ratings

CYTK

Cantor Fitzgerald Reiterates Overweight on Cytokinetics

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

Price Target

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Cytokinetics Will Provide An Update On Cardiac Myosin Modulation Programs And Global Commercial Launch Readiness For Aficamten At Its Investor And Analyst Day Today

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) price target from $75 to $85. Needham analyst Laura Martin maintained a Buy rating. Reddit shares gained 0.5% to close at $70.77 on Tuesday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised the price target for Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from $90 to $120. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Cytokinetics shares fell 2.1% to close at $54.33 on Tuesday. <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from $13 to $9. Baird analyst Joel Beatty maintained a Neutral rating. Sage Therapeutics shares fell 4.3% to close at $6.43 on Tuesday. <a href="https://www.benzinga.com/quote/SAGE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) price target from $79 to $90. Baird analyst Colin Sebastian maintained an Outperform rating. Shopify shares gained 2.1% to close at $82.58 on Tuesday. <a href="https://www.benzinga.com/quote/SHOP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $590 to $650. Deutsche Bank analyst Bryan Kraft maintained a Hold rating. Netflix shares gained 2.8% to close at $721.76 on Tuesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital raised The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) price target from $360 to $460. Loop Capital analyst Laura Champine upgraded the stock from Hold to Buy. Home Depot shares gained 1.5% to close at $414.18 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased the price target for Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from $60 to $63. Morgan Stanley analyst Meta Marshall maintained an Overweight rating. Ciena rose 2.6% to close at $65.25 on Tuesday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $564 to $570. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. S&amp;P Global shares gained 2.4% to close at $518.35 on Tuesday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities raised the price target for Blue Owl Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) from $24 to $25. JMP Securities analyst Brian McKenna maintained a Market Outperform rating. Blue Owl Capital shares fell 1.8% to close at $20.35 on Tuesday. <a href="https://www.benzinga.com/quote/OWL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) price target from $38 to $44. Baird analyst David Koning maintained a Neutral rating. Genpact shares fell 1.6% to close at $38.92 on Tuesday. <a href="https://www.benzinga.com/quote/G/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think:
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/e01feb48-33dc-4d9a-8aab-90248ce8208f" alt="" style="width:557px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CIEN

NFLX

RDDT

SAGE

SHOP

SPGI

Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and raises the price target from $90 to $120.

HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $120

Edgewise Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ewtx#NASDAQ">EWTX</a>) is a small-cap <a href="https://www.marketbeat.com/compare-stocks/pharmaceutical-stocks/">pharmaceutical stock</a> that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks. Yet, with still only a market cap of $2.4 billion, is there still time to get in? I&#39;ll examine recent news around the company, its <a href="https://edgewisetx.com/science-pipeline/pipeline/">drug pipeline</a>, and what Wall Street is saying to get a better handle on this question.
<h3>Edgewise&#39;s Muscular Dystrophy Treatments Have Large Market Than Others</h3>
Edgewise currently has two drugs that are driving the company. They are Sevasemten and EDG-7500. The company is researching Sevasemten to treat muscular dystrophy (MD). One interesting thing about this medicine is that it is being researched to treat multiple types of MD.
Specifically, it is currently in Phase 3 trials to treat Becker MD and in Phase 2 trials for Duchenne MD. Many medicines are being researched only on one form of MD. So, the possibility that they could apply to both is a strong differentiator for the company.
However, this is likely because the treatment manages symptoms. It does not target the genetic cause of Duchenne MD. The root cause of Duchenne and Becker is different, but the symptoms are similar.
Still, this treatment could be valuable and could theoretically be used in conjunction with genetic treatments. The focus on treatment management opens the product up to the entire MD market rather than a sliver of it; another potential benefit.
In its latest results for Becker, the drug showed it actually slightly improved muscle function after 24 months. Those given a placebo showed significantly worse function. Becker MD currently has no approved treatments. The company estimates there are currently around 47,000 people with one of the diseases in the US, EU, and Japan combined.
<h3>&nbsp;EDG-7500 Results Show It Keeps Up With The Competition</h3>
The company&#39;s other main drug, EDG-7500, is a cardiovascular medicine. Specifically, it works to treat hypertrophic cardiomyopathy (HCM). Recent good news around this drug was why shares of Edgewise <a href="https://www.marketbeat.com/stock-ideas/edgewise-therapeutics-soars-50-key-reasons-behind-the-surge/">jumped 50% in one day</a>. HCM primarily affects the left ventricle of the heart, causing its walls to thicken. The left ventricle is the main pumping station of the heart. pumped. The thickening makes it hard for the left ventricle to pump blood and can result in heart failure.
On average, the study revealed that a biomarker linked to heart stress decreased by 64%. Another measurement of how well the heart is pumping blood is the left ventricular ejection fraction (LVEF).
The results showed that all the patients maintained a normal level of LVEF. Thus, the treatment reduced stress on the heart without interfering with its ability to pump. The market for this treatment is much larger, affecting up to 630,000 people in the United States alone.
However, HCM does have an approved treatment: <a href="https://www.marketbeat.com/stocks/NYSE/BMY/">Bristol Myers Squibb&#39;s (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) Camzyos. The drug showed a <a href="https://news.bms.com/news/corporate-financial/2022/Mavacamten-Demonstrated-Significant-Reduction-in-Need-for-Septal-Reduction-Therapy-in-Symptomatic-Obstructive-HCM-Patients-in-Phase-3-VALOR-Trial/default.aspx#:~:text=Improvement%20in%20biomarkers%20of%20cardiac,greater%20(p%3C0.0001).">67% reduction</a> in the same biomarker as EDG-7500. However, a very small number of patients did see their LVEF levels fall below normal. At this point, the drugs appear to have similar levels of safety and efficacy. Two and a half years ago, Camzyos received approval. It generated $139 million last quarter, up by 184% from the previous year.
<a href="https://www.marketbeat.com/stocks/NASDAQ/CYTK/">Cytokinetics&#39; (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/cytk#NASDAQ">CYTK</a>) aficamten, another competitor, is further along but has yet to receive approval. <a href="https://www.fiercebiotech.com/biotech/edgewise-therapeutics-heart-med-candidate-sends-shares-soaring-early-data">According to Fierce Biotech</a>, analysts at Mizuho Securities say the results of the two drugs look similar.
When it comes to Wall Street, several analysts still see significant upside in Edgewise. At least four firms have increased their price targets on Edgewise since it released Phase 2 results for EDG-7500.
Based on the average of those four targets, the implied upside of Edgewise is 55%, based on the Sept. 24 closing price of nearly $26. The most bullish analyst, Wedbush, thinks Edgewise could rise 70%.
<h3>Final Thoughts On Edgewise</h3>
At the end of the day, the party is certainly not over for Edgewise until it is. More good news about the drug treatments would continue to boost the stock price. But, it will take a long time for sales to justify its high valuation. The probability of treatments getting approved is low, at around <a href="https://www.cbo.gov/publication/57126#:~:text=Only%20about%2012%20percent%20of,than%20%242%20billion%20per%20drug.">12% on average</a>.
The results of EDG-7500 do show promise not only in their comparability to the already approved treatment but also in the revenue that Bristol-Myers has demonstrated. However, with Sevasemten in Phase 3 trials for Becker MD, the company could be the first to get an approved treatment in that market.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/analyst-think-theres-still-time-to-get-in-on-edgewise-up-332/">Analysts Think There&#39;s Still Time to Get in on Edgewise, Up 332%</a>&quot; first appeared on MarketBeat.

Biotech

Small Cap

General

EWTX

Analysts Think There's Still Time To Get In On Edgewise

Responder Analyses Show Treatment with Aficamten Demonstrated Improvements&nbsp; on Multiple Assessments of Clinical Significance to Cardiologists
Results Simultaneously Published in&nbsp; the Journal of the American College of Cardiology

Events

Cytokinetics Presents Additional SEQUOIA-HCM Data At HFSA Annual Scientific Meeting

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $90 price target.

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions by Anjali T. Owens, M.D., Medical Director of the Center for Inherited Cardiac Disease and Assistant Professor of Medicine at the University of Pennsylvania. &nbsp;
A new analysis from SEQUOIA-HCM showed that treatment with aficamten was associated with beneficial changes in five indices reflecting structural, electrophysiologic and biomarker changes in patients from SEQUOIA-HCM. This analysis was performed in patients treated with aficamten and compared to placebo, at 24 weeks as follows:
<ul>
<li>Improvement in maximal wall thickness by ≥1.5 mm (n = 282; 47.9% vs 30.7%; p=0.003)</li>
<li>Improvement in left atrial volume index (LAVI) category in those with mild, moderate, or severe enlargement at baseline (n = 185; 46.8% vs. 18.7%; p&lt;0.001)</li>
<li>Resolution of ECG changes consistent with left ventricular hypertrophy (n = 282; 19.0% vs. 4.3%; p&lt;0.001)</li>
<li>Normalization of hyperdynamic left ventricular ejection fraction (defined as ≥72%) into the normal range (n = 282; 35.2% vs 20.7%; p&lt;0.007)</li>
<li>Reduction in NT-proBNP by ≥50% from baseline (n = 282; 81.7% vs. 7.1%; p&lt;0.001). &nbsp;</li>
</ul>
Overall, 83.8% of patients treated with aficamten experienced favorable effects in at least one of the five domains, compared to 39.3% of patients on placebo (p&lt;0.001, NNT = 2.2).

Cytokinetics Presents Additional Data From SEQUOIA-HCM At The HCMS Scientific Sessions; Says "Overall, 83.8% Of Patients Treated With Aficamten Experienced Favorable Effects In At Least One Of The Five Domains, Compared To 39.3% Of Patients On Placebo"

Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced three upcoming presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on September 27, 2024 and one Late Breaking Clinical Trial presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place September 27-30, 2024, both in Atlanta, GA.

Cytokinetics Announces Upcoming Presentations At The HCMS Scientific Sessions And The HFSA Annual Scientific Meeting

High-rolling investors have positioned themselves bearish on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CYTK often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Cytokinetics. This is not a typical pattern.
The sentiment among these major traders is split, with 22% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $78,210, and 8 calls, totaling $454,049.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for Cytokinetics, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Cytokinetics options trades today is 2869.17 with a total volume of 1,920.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Cytokinetics's big money trades within a strike price range of $55.0 to $75.0 over the last 30 days.
<h3>Cytokinetics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726247312_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.6</td>
<td>$4.1</td>
<td>$4.6</td>
<td>$55.00</td>
<td>$108.2K</td>
<td>4</td>
<td style="text-align: right;">408</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.7</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$79.5K</td>
<td>13.0K</td>
<td style="text-align: right;">348</td>
</tr>
<tr>
<td>CYTK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.3</td>
<td>$2.9</td>
<td>$3.3</td>
<td>$55.00</td>
<td>$78.2K</td>
<td>312</td>
<td style="text-align: right;">450</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.6</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$52.0K</td>
<td>13.0K</td>
<td style="text-align: right;">303</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.8</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$60.00</td>
<td>$46.4K</td>
<td>1.4K</td>
<td style="text-align: right;">32</td>
</tr>
</tbody>
</table>

<h3>About Cytokinetics</h3>
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Having examined the options trading patterns of Cytokinetics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Cytokinetics's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 246,671, the CYTK's price is up by 3.37%, now at $55.88. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cytokinetics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Cytokinetics's Options Frenzy: What You Need to Know

Monday, Cytokinetics, Incorporated&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology Annual <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40770281/cytokinetics-announces-data-from-phase-1-study-of-ck-4021586" rel="noreferrer noopener">Meeting in Bethesda, MD</a>.
The study met its primary and secondary objectives to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple oral doses of CK-586.
CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of patients with symptomatic HFpEF with hypercontractility and ventricular hypertrophy.
The study data showed that CK-586 was safe and well tolerated in healthy participants.
No serious adverse events were observed, and the stopping criteria for the study were not met.
The half-life of CK-586 was observed to be in the range of 14 to 17 hours.
CK-586 demonstrated dose-linearity without a change in half-life over a wide range of exposures, with steady-state appearing evident within seven days of dosing.
Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) decreased from baseline in an exposure-dependent manner, and the pharmacokinetic/pharmacodynamic (PK/PD) relationship appeared shallow and predictable.
The ejection fraction measures how well the heart is functioning. It's expressed as a percentage and indicates how much blood the heart pumps out with each contraction. At the highest single dose of 600 mg, the mean decrease in LVEF was &lt;5%.
These results demonstrate pharmacologic properties that may enable once-daily fixed-dose administration in the future. Preparations for a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) are underway, and the trial is expected to begin in the fourth quarter of 2024.
Price Action: CYTK stock is up 2.71% at $55.56 at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40776938/stellantis-recalls-1-46m-vehicles-globally-over-safety-software-flaw-details" target="_blank" rel="noreferrer noopener">Stellantis Recalls 1.46M Vehicles Globally Over Safety Software Flaw: Details</a>.</li>
</ul>

Equities

Health Care

Movers

Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, MD. The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple oral doses of CK-586. The data support the advancement of CK-586 to a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which is expected to begin in Q4 2024. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of patients with symptomatic HFpEF with hypercontractility and ventricular hypertrophy.

Cytokinetics' CK-586 Advances After Phase 1 Results, Phase 2 Trial Set for Late 2024

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced two presentations at the 2024 American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, MD from September 8, 2024 – September 10, 2024. &nbsp;

Cytokinetics Announces Two Presentations At The 2024 ACCP Annual Meeting September 8, 2024 – September 10, 2024

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Overweight and raises the price target from $65 to $71.

JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $71

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Cytokinetics (CYTK – Research Report). The associated price target remai...

Cytokinetics: Strategic Growth and Promising Cardiology Pipeline Justify Buy Rating

In a report released today, Carter Gould from Barclays maintained a Buy rating on Cytokinetics (CYTK – Research Report), with a price target of $95...

Barclays Remains a Buy on Cytokinetics (CYTK)

Jason Zemansky, an analyst from Bank of America Securities, maintained the Hold rating on Cytokinetics (CYTK – Research Report). The associated pri...

Cytokinetics Hold Rating: Balancing Promising Commercial Strategy with Execution Risks and Market Uncertainties

Analyst Serge Belanger of Needham maintained a Buy rating on Cytokinetics (CYTK – Research Report), retaining the price target of $72.00. Serge Bel...

Cytokinetics' Strategic Cardiology Franchise Poised for Growth with Aficamten and Expanding Pipeline

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company's shares closed yesterday at $55.28. According ...

Truist Financial Releases a Buy Rating on Cytokinetics (CYTK)

Jefferies analyst Akash Tewari maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $92.00. The company...

Jefferies Remains a Buy on Cytokinetics (CYTK)

Mizuho Securities analyst Salim Syed has maintained their bullish stance on CYTK stock, giving a Buy rating today. Salim Syed has given his Buy rat...

Cytokinetics: Strategic Cardiology Expansion and Market Potential Drive Buy Rating

Oppenheimer buy-rated ideas: BSX, MDT, and one hold: CYTK

B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on CYTK stock, giving a Buy rating on October 17. Mayank Mamtani has g...

Comments

Cytokinetics

Vendite allo scoperto

Cytokinetics (NASDAQ:CYTK) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO